China Resources Double-Crane (600062.SH) Subsidiary TIAN AN Passes GMP Compliance Inspection

Stock News11-13

China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the "Drug GMP Compliance Inspection Notice" (No.: Qian 20250059) issued by the Guizhou Provincial Drug Administration.

The inspection covered the following scope and related workshops/production lines: - Tablet production [Metformin Empagliflozin Tablets (I) (each tablet contains 500mg metformin hydrochloride and 5mg empagliflozin)], - Comprehensive Workshop (IV) tablet production line (self-produced). The designed annual production capacity of the line is 500 million tablets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1138105026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1138105026","market":"sh","top_or_hot":-1,"title":"China Resources Double-Crane (600062.SH) Subsidiary TIAN AN Passes GMP Compliance Inspection","media":"Stock News","content":"<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No.: Qian 20250059) issued by the Guizhou Provincial Drug Administration.</p>\n<p>The inspection covered the following scope and related workshops/production lines:  \n- Tablet production [Metformin Empagliflozin Tablets (I) (each tablet contains 500mg metformin hydrochloride and 5mg empagliflozin)],  \n- Comprehensive Workshop (IV) tablet production line (self-produced).  \nThe designed annual production capacity of the line is 500 million tablets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Double-Crane (600062.SH) Subsidiary TIAN AN Passes GMP Compliance Inspection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Double-Crane (600062.SH) Subsidiary TIAN AN Passes GMP Compliance Inspection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-13 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No.: Qian 20250059) issued by the Guizhou Provincial Drug Administration.</p>\n<p>The inspection covered the following scope and related workshops/production lines:  \n- Tablet production [Metformin Empagliflozin Tablets (I) (each tablet contains 500mg metformin hydrochloride and 5mg empagliflozin)],  \n- Comprehensive Workshop (IV) tablet production line (self-produced).  \nThe designed annual production capacity of the line is 500 million tablets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1138105026","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1138105026","pubTimestamp":1763024420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug GMP Compliance Inspection...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0028":"国家队","BK0239":"医药制造","BK0185":"二线龙头","00028":"天安","BK0188":"融资融券","BK0175":"白马股","BK0010":"央企","BK1240":"房地产开发"},"translate_title":"华润双鹤（600062.SH）子公司天安通过GMP符合性检查","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":1,"00028":1},"content_text":"China Resources Double-Crane Pharmaceutical Co., Ltd. (600062.SH) announced that its subsidiary, TIAN AN Pharmaceutical (Guizhou) Co., Ltd., recently received the \"Drug GMP Compliance Inspection Notice\" (No.: Qian 20250059) issued by the Guizhou Provincial Drug Administration.\nThe inspection covered the following scope and related workshops/production lines:  \n- Tablet production [Metformin Empagliflozin Tablets (I) (each tablet contains 500mg metformin hydrochloride and 5mg empagliflozin)],  \n- Comprehensive Workshop (IV) tablet production line (self-produced).  \nThe designed annual production capacity of the line is 500 million tablets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1138105026","isCrawlerRequest":true}